A novel chromogenic in situ hybridization assay for FGF23 mRNA in phosphaturic mesenchymal tumors

American Journal of Surgical Pathology

Volumn 39, Issue 1, 2015, Pages 75-83

  Carter, Jodi M ^a   Caron, Bolette L ^a   Dogan, Ahmet ^b   Folpe, Andrew L ^a  

^a MAYO CLINIC   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Chromogenic in situ hybridization; FGF23; Mrna; Osteomalacia; Phosphaturic mesenchymal tumor

Indexed keywords

CHROMOGENIC SUBSTRATE; FIBROBLAST GROWTH FACTOR; FIBROBLAST GROWTH FACTOR 23; MESSENGER RNA; TUMOR MARKER;

ADULT; AGED; BIOPSY; CHEMISTRY; COMPARATIVE STUDY; CONNECTIVE TISSUE TUMOR; DIAGNOSTIC USE; EVALUATION STUDY; FEMALE; GENETICS; HUMAN; IN SITU HYBRIDIZATION; LABORATORY DIAGNOSIS; MALE; MESODERM; MIDDLE AGED; PATHOLOGY; PREDICTIVE VALUE; PRESCHOOL CHILD; PROCEDURES; REPRODUCIBILITY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ADULT; AGED; BIOPSY; CHILD, PRESCHOOL; CHROMOGENIC COMPOUNDS; FALSE POSITIVE REACTIONS; FEMALE; FIBROBLAST GROWTH FACTORS; HUMANS; IN SITU HYBRIDIZATION; MALE; MESODERM; MIDDLE AGED; NEOPLASMS, CONNECTIVE TISSUE; PREDICTIVE VALUE OF TESTS; REPRODUCIBILITY OF RESULTS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TUMOR MARKERS, BIOLOGICAL;

EID: 84919341494     PISSN: 01475185     EISSN: 15320979     Source Type: Journal    
DOI: 10.1097/PAS.0000000000000290     Document Type: Article

References (45)

1. Nanes MS. Phosphate wasting and fibroblast growth factor-23. Curr Opin Endocrinol Diabetes Obes. 2013;20:523-531.
2. Chong WH, Molinolo AA, Chen CC, et al. Tumor-induced osteomalacia. Endocr Relat Cancer. 2011;18:R53-R77.
3. McMurtry CT, Godschalk M, Malluche HH, et al. Oncogenic osteomalacia associated with metastatic prostate carcinoma: case report and review of the literature. J Am Geriatr Soc. 1993;41: 983-985.
4. Nakahama H, Nakanishi T, Uno H, et al. Prostate cancer-induced oncogenic hypophosphatemic osteomalacia. Urol Int. 1995;55: 38-40.
5. Rai GS. Oncogenic osteomalacia associated with metastatic prostate carcinoma [comment]. J Am Geriatr Soc. 1994;42:688.
6. Reese DM, Rosen PJ. Oncogenic osteomalacia associated with prostate cancer. J Urol. 1997;158:887.
7. Weidner N, Santa Cruz D. Phosphaturic mesenchymal tumors. A polymorphous group causing osteomalacia or rickets. Cancer. 1987;59:1442-1454.
8. Folpe AL, Fanburg-Smith JC, Billings SD, et al. Most osteomalacia- associated mesenchymal tumors are a single histopathologic entity: an analysis of 32 cases and a comprehensive review of the literature. Am J Surg Pathol. 2004;28:1-30.
9. Fletcher CDM, Bridge JA, Hogendoorn PCW. WHO Classification of Tumours of Soft Tissue and Bone. Lyons: IARC Press; 2013.
10. Berndt T, Craig TA, Bowe AE, et al. Secreted frizzled-related protein 4 is a potent tumor-derived phosphaturic agent. J Clin Invest. 2003;112:785-794.
11. Kumar R. New insights into phosphate homeostasis: fibroblast growth factor 23 and frizzled-related protein-4 are phosphaturic factors derived from tumors associated with osteomalacia. Curr Opin Nephrol Hypertens. 2002;11:547-553.
12. Bowe AE, Finnegan R, Jan de Beur SM, et al. FGF-23 inhibits renal tubular phosphate transport and is a PHEX substrate. Biochem Biophys Res Commun. 2001;284:977-981.
13. Kumar R. Phosphatonin-a new phosphaturetic hormone? (lessons from tumour-induced osteomalacia and X-linked hypophosphataemia). Nephrol Dial Transplant. 1997;12:11-13.
14. Fukumoto S, Yamashita T. FGF23 is a hormone-regulating phosphate metabolism-unique biological characteristics of FGF23. Bone. 2007;40:1190-1195.
15. Shimada T, Mizutani S, Muto T, et al. Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia. Proc Natl Acad Sci USA. 2001;98:6500-6505.
16. Bhattacharyya N, Chong WH, Gafni RI, et al. Fibroblast growth factor 23: state of the field and future directions. Trends Endocrinol Metab. 2012;23:610-618.
17. Kuro-o M. Overview of the FGF23-Klotho axis. Pediatr Nephrol. 2010;25:583-590.
18. Shimada T, Urakawa I, Yamazaki Y, et al. FGF-23 transgenic mice demonstrate hypophosphatemic rickets with reduced expression of sodium phosphate cotransporter type IIa. Biochem Biophys Res Commun. 2004;314:409-414.
19. Perwad F, Zhang MY, Tenenhouse HS, et al. Fibroblast growth factor 23 impairs phosphorus and vitamin D metabolism in vivo and suppresses 25-hydroxyvitamin D-1alpha-hydroxylase expression in vitro. Am J Physiol Renal Physiol. 2007;293:F1577-F1583.
20. Saito H, Maeda A, Ohtomo S, et al. Circulating FGF-23 is regulated by 1alpha, 25-dihydroxyvitamin D3 and phosphorus in vivo. J Biol Chem. 2005;280:2543-2549.
21. Houang M, Clarkson A, Sioson L, et al. Phosphaturic mesenchymal tumors show positive staining for somatostatin receptor 2A (SSTR2A). Hum Pathol. 2013;44:2711-2718.
22. Bahrami A, Weiss SW, Montgomery E, et al. RT-PCR analysis for FGF23 using paraffin sections in the diagnosis of phosphaturic mesenchymal tumors with and without known tumor induced osteomalacia. Am J Surg Pathol. 2009;33:1348-1354.
23. Graham R, Krishnamurthy S, Oliveira A, et al. Frequent expression of fibroblast growth factor-23 (FGF23) mRNA in aneurysmal bone cysts and chondromyxoid fibromas. J Clin Pathol. 2012;65: 907-909.
24. Wang F, Flanagan J, Su N, et al. RNAscope: a novel in situ RNA analysis platform for formalin-fixed, paraffin-embedded tissues. J Mol Diagn. 2012;14:22-29.
25. McCance RA. Osteomalacia with Loosers nodes (Milkmans Syndrome) due to a raised resistance to Vitamin D acquired about the age of 15 years. Q J Med. 1947;16:33-46.
26. Prader A, Illig R, Uehlinger RE, et al. Rachitis infolge knochentumors [Rickets caused by bone tumors]. Helv Pediatr Acta. 1959;14:554-565.
27. Evans DJ, Azzopardi JG. Distinctive tumours of bone and soft tissue causing acquired vitamin-D-resistant osteomalacia. Lancet. 1972;1:353-354.
28. Olefsky J, Kempson R, Jones H, et al. Tertiary hyperparathyroidism and apparent cure of vitamin-D-resistant rickets after removal of an ossifying mesenchymal tumor of the pharynx. N Engl J Med. 1972;286:740-745.
29. Goldblum JR, Folpe AL, Weiss SW, et al. Enzinger and Weisss Soft Tissue Tumors. Philadelphia, PA: Saunders/Elsevier; 2014.
30. Ogose A, Hotta T, Emura I, et al. Recurrent malignant variant of phosphaturic mesenchymal tumor with oncogenic osteomalacia. Skeletal Radiol. 2001;30:99-103.
31. Sidell D, Lai C, Bhuta S, et al. Malignant phosphaturic mesenchymal tumor of the larynx. Laryngoscope. 2011;121:1860-1863.
32. Uchihashi K, Nishijima-Matsunobu A, Matsuyama A, et al. Phosphaturic mesenchymal tumor, nonphosphaturic variant, causing fatal pulmonary metastasis. Hum Pathol. 2013;44: 2614-2618.
33. Uramoto N, Furukawa M, Yoshizaki T. Malignant phosphaturic mesenchymal tumor, mixed connective tissue variant of the tongue. Auris Nasus Larynx. 2009;36:104-105.
34. Imanishi Y, Hashimoto J, Ando W, et al. Matrix extracellular phosphoglycoprotein is expressed in causative tumors of oncogenic osteomalacia. J Bone Miner Metab. 2012;30:93-99.
35. Argiro L, Desbarats M, Glorieux FH, et al. MEPE, the gene encoding a tumor-secreted protein in oncogenic hypophosphatemic osteomalacia, is expressed in bone. Genomics. 2001;74:342-351.
36. Rowe PS, de Zoysa PA, Dong R, et al. MEPE, a new gene expressed in bone marrow and tumors causing osteomalacia. Genomics. 2000;67:54-68.
37. Tebben PJ, Kalli KR, Cliby WA, et al. Elevated fibroblast growth factor 23 in women with malignant ovarian tumors. Mayo Clin Proc. 2005;80:745-751.
38. Leaf DE, Pereira RC, Bazari H, et al. Oncogenic osteomalacia due to FGF23-expressing colon adenocarcinoma. J Clin Endocrinol Metab. 2013;98:887-891.
39. Ben-Baruch D, Ziv Y, Sandbank J, et al. Oncogenic osteomalacia induced by schwannoma in a patient with neurofibromatosis. Eur J Surg Oncol. 1994;20:57-61.
40. Haviv YS, Silver J. Late onset oncogenic osteomalacia-associated with neurofibromatosis type II. Clin Nephrol. 2000;54:429-430.
41. Jagtap VS, Sarathi V, Lila AR, et al. Tumor Induced Osteomalacia: a single center experience. Endocr Pract. 2010;17:1-19.
42. Lever EG, Pettingale KW. Albrights syndrome associated with a soft-tissue myxoma and hypophosphataemic osteomalacia. Report of a case and review of the literature. J Bone Joint Surg Br. 1983;65:621-626.
43. Park YK, Unni KK, Beabout JW, et al. Oncogenic osteomalacia: a clinicopathologic study of 17 bone lesions. J Korean Med Sci. 1994;9:289-298.
44. Riminucci M, Collins MT, Fedarko NS, et al. FGF-23 in fibrous dysplasia of bone and its relationship to renal phosphate wasting. J Clin Invest. 2003;112:683-692.
45. Yamamoto T, Miyamoto KI, Ozono K, et al. Hypophosphatemic rickets accompanying McCune-Albright syndrome: evidence that a humoral factor causes hypophosphatemia. J Bone Miner Metab. 2001;19:287-295.